CD19 molecule. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Blinatumomab CHEMBL1742992 |
B-lymphocyte antigen CD19 cross-linking agent Cross-linking agent Antibody |
✓ Both | 49 |
| Tafasitamab CHEMBL4298047 |
B-lymphocyte antigen CD19 binding agent Binding agent Antibody |
✓ Both | 14 |
| Axicabtagene Ciloleucel CHEMBL3989989 |
B-lymphocyte antigen CD19 binding agent Binding agent Gene |
ChEMBL only | 13 |
| Inebilizumab CHEMBL2109334 |
B-lymphocyte antigen CD19 binding agent Binding agent Antibody |
✓ Both | 12 |
| Lisocabtagene maraleucel CHEMBL4297236 |
B-lymphocyte antigen CD19 binding agent Binding agent Gene |
ChEMBL only | 9 |
| Loncastuximab Tesirine CHEMBL4297778 |
B-lymphocyte antigen CD19 binding agent Binding agent Antibody drug conjugate |
✓ Both | 6 |
| Tisagenlecleucel CHEMBL3301574 |
B-lymphocyte antigen CD19 binding agent Binding agent Cell |
ChEMBL only | 5 |
| Obexelimab CHEMBL4298134 |
B-lymphocyte antigen CD19 inhibitor Inhibitor Antibody |
ChEMBL only | 4 |
| Obecabtagene autoleucel CHEMBL5095440 |
B-lymphocyte antigen CD19 binding agent Binding agent Gene |
ChEMBL only | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Non-Hodgkin lymphoma | 7 | Phase 3 |
| B-cell chronic lymphocytic leukemia | 5 | Phase 3 |
| Acute lymphoblastic leukemia | 5 | Phase 3 |
| Mantle cell lymphoma | 5 | Phase 2/3 |
| Primary central nervous system lymphoma | 5 | Phase 2 |
| High grade B-cell lymphoma | 4 | Phase 3 |
| Hematopoietic and lymphoid cell neoplasm | 4 | Phase 2 |
| Lymphoma | 4 | Phase 2 |
| B-cell non-Hodgkin lymphoma | 4 | Phase 1/2 |
| Follicular lymphoma | 3 | Phase 3 |
| Marginal zone lymphoma | 3 | Phase 3 |
| Burkitt lymphoma | 3 | Phase 2 |
| Richter transformation | 3 | Phase 2 |
| Leukemia | 3 | Phase 2 |
| Multiple sclerosis symptom measurement | 3 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
